Study to Assess the Safety and Tolerability of Incremental Doses of QAB149 in Adults With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria: * Male and/or female patients with mild to moderate stable COPD, diagnosed according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; 40-75 years of age * Prebronchodilator baseline forced expiratory volume in 1 second (FEV1) 30-80% of the Quanjer predicted normal value (Quanjer et al. 1993) and at least 0.75 L with FEV1/forced vital capacity (FVC) \< 70% of predicted \[GOLD guidelines\]. * Previous smokers (\>10 pack-years). Ten pack years are defined as: 20 cigarettes a day for 10 years; 10 cigarettes a day for 20 years; or 40 cigarettes a day for 5 years. Current smokers, with \>10 pack year history, can be included under certain conditions. * Vital signs (after 3 minutes resting measured in the supine position) which are within the following ranges: * oral body temperature between 35.0-37.5 °C; * systolic blood pressure, 100-170 mm Hg; * diastolic blood pressure, 50-100 mm Hg; * pulse rate, 50 - 90 beats per minute (bpm). * Patients must weigh a minimum of 50 kg to participate in this study. * Able to provide written informed consent prior to study participation. * Able to communicate well with the investigator and comply with the requirements of the study. Exclusion Criteria: * Pregnant women or nursing mothers. * Patients with a QTc interval above 0.43 seconds for males and 0.45 seconds for females at the screening visit. If pre-treatment values on Day 1 of the treatment periods exceed 0.45 and 0.47 seconds for males and females respectively the visit may be re-scheduled once. * Patients with a history of prolonged QTc intervals, or a family history of prolonged QT syndrome. * Predominant diagnosis of asthma. (Patients must present without evidence of active asthma.) * Patients who have been hospitalized or had emergency treatment for acute COPD exacerbation in the one month prior to or during screening. * Patients who have had a respiratory tract infection within one month prior to screening. * Patients with concomitant pulmonary disease, including a history of cancer Other exclusion criteria apply.